TABLE 1.
Patient characteristics
| Group | Fluvoxamine + standard therapy | Standard therapy | P‐value | ||
|---|---|---|---|---|---|
| Male | Female | Male | Female | ||
| No. of patients | 34 (66.7%) | 17 (33.3%) | 34 (66.7%) | 17 (33.3%) | |
| Age, years (mean ± SD) | 65 ± 12 | 66.82 ± 11.52 | 65.59 ± 11.9 | 66.71 ± 11.49 | 0.987 |
| Age >65 years | 20 (39%) | 12 (70.6%) | 20 (39%) | 12 (70.6%) | |
| Age 50–64 years | 10 (20%) | 3 (17.7%) | 10 (20%) | 3 (17.7%) | |
| Race/ethnicity | |||||
| Caucasian | 34 (100%) | 17 (100%) | 34 (100%) | 17 (100%) | |
| BMI (mean ± SD) | 28.70 ± 5.39 | 29.15 ± 3.95 | 30.13 ± 4.36 | 31.28 ± 8.48 | 0.129 |
| Chronic comorbidity | |||||
| Diabetes | 9 (27%) | 3 (17.7%) | 9 (27%) | 5 (29%) | 0.653 |
| Hypertension, treated | 19 (56%) | 12 (70.6%) | 25 (74%) | 13 (76.5%) | 0.141 |
| Coronary artery disease | 4 (11.8%) | 3 (17.6%) | 2 (5.9%) | 0 | 0.08 |
| COPD | 2 (6%) | 0 | 4 (12%) | 1 (6%) | 0.245 |
| Cerebrovascular disease | 1 (3%) | 1 (6%) | 0 | 0 | 0.159 |
| Chronic renal insufficiency | 3 (9%) | 0 | 2 (6%) | 1 (6%) | 1 |
| Hepatic cirrhosis | 1 (3%) | 0 | 0 | 2 (11.8%) | 0.563 |
| Apache II score (mean ± SD) | 13.3 ± 5.1 | 13.9 ± 5.9 | 0.545 | ||
| SOFA score (mean ± SD) | 3.9 ± 2.3 | 4.1 ± 2.5 | 0.651 | ||
| COVID‐19 vaccination | 6 (11.8%) | 6 (11.8%) | 1 | ||